| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.aventispharmaindia.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 19,679.78 Cr. | |
| Earnings per share (EPS) | 251.88 | Trailing Twelve Months Ending 2021-06 |
| Price-Earning Ratio (PE) | 33.92 | Trailing Twelve Months Ending 2021-06 |
| Industry PE | 32.66 | Trailing Twelve Months Ending 2021-06 |
| Book Value / Share | 697.04 | Trailing Twelve Months Ending 2021-06 |
| Price to Book Value | 12.26 | Calculated using Price: 8,545.05 |
| Dividend Yield | 4.27 | Period Ending 2020-12 |
| No. of Shares Subscribed | 2.30 Cr. | 23,030,622 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries. Business area of the company The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. Products Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo). Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip) Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD, Milestones
|
||
Company Profile
Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.
Business area of the company
The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
Products
Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).
Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)
Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)
Milestones
| 1 Day |
|
+0.63% |
| 1 Week |
|
+8.03% |
| 1 Month |
|
+11.85% |
| 3 Month |
|
+12.24% |
| 6 Month |
|
+9.02% |
| 1 Year |
|
+3.52% |
| 2 Year |
|
+41.74% |
| 5 Year |
|
+89.22% |
| 9 years | 2012-12 | 2013-12 | 2014-12 | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | |
| Return on Equity (%) | 15.38 | 20.97 | 18.70 | 20.68 | 17.43 | 16.87 | 18.18 | 18.07 | 21.39 | |
| Return on Capital Employed (%) | 22.90 | 30.75 | 26.47 | 30.96 | 27.51 | 26.38 | 28.76 | 25.75 | 29.77 | |
| Return on Assets (%) | 11.27 | 15.11 | 12.84 | 13.88 | 12.30 | 9.50 | 8.37 | 8.28 | 9.24 |
| Particulars | 9 years | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. |
| Shh. Funds | 1,204 | 1,347 | 1,486 | 1,627 | 1,883 | 2,026 | 2,219 | 2,442 | 2,119 | |
| Non Curr. Liab. | 41 | 63 | 86 | 161 | 156 | 1,335 | 1,357 | 1,124 | 1,280 | |
| Curr. Liab. | 387 | 469 | 656 | 617 | 502 | 962 | 1,193 | 1,674 | 1,694 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 1,631 | 1,878 | 2,228 | 2,405 | 2,541 | 4,324 | 4,769 | 5,240 | 5,093 | |
| Non Curr. Assets | 803 | 931 | 965 | 1,161 | 966 | 2,519 | 2,608 | 2,141 | 2,253 | |
| Curr. Assets | 829 | 947 | 1,263 | 1,244 | 1,575 | 1,805 | 2,162 | 3,099 | 2,841 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 1,631 | 1,878 | 2,228 | 2,405 | 2,541 | 4,324 | 4,769 | 5,240 | 5,093 |
| Particulars | 9 years | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. |
| Net Sales | 1,573 | 1,809 | 1,977 | 2,193 | 2,367 | 2,464 | 2,771 | 3,071 | 2,902 | |
| Other Income | 41 | 58 | 64 | 51 | 66 | 81 | 90 | 94 | 90 | |
| Total Income | 1,614 | 1,867 | 2,042 | 2,245 | 2,433 | 2,544 | 2,861 | 3,165 | 2,992 | |
| Total Expenditure | -1,261 | -1,411 | -1,639 | -1,734 | -1,832 | -1,926 | -2,148 | -2,405 | -2,189 | |
| PBIDT | 353 | 456 | 403 | 511 | 602 | 618 | 713 | 759 | 803 | |
| Interest | -1 | 0 | 0 | 0 | -2 | -1 | -1 | 0 | -2 | |
| Depreciation | -90 | -92 | -97 | -113 | -119 | -102 | -103 | -100 | -82 | |
| Taxation | -85 | -123 | -109 | -159 | -176 | -189 | -229 | -186 | -200 | |
| Exceptional Items | 25 | 67 | 84 | -59 | -42 | |||||
| PAT | 177 | 265 | 264 | 322 | 304 | 326 | 381 | 414 | 478 |
| Particulars | 9 years | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. |
| Cash Fr. Operatn. | 290 | 273 | 265 | 213 | 322 | 435 | 374 | 412 | 611 | |
| Cash Fr. Inv. | -5 | -335 | 61 | 36 | -155 | -79 | -73 | 66 | 276 | |
| Cash Fr. Finan. | -90 | -105 | -122 | -147 | -180 | -188 | -197 | -183 | -810 | |
| Net Change | 195 | -168 | 205 | 102 | -13 | 168 | 104 | 295 | 78 | |
| Cash & Cash Eqvt | 429 | 261 | 466 | 568 | 554 | 722 | 825 | 1,120 | 1,197 |
|
Wed, 28 Jul 2021
Slump Sale And Transfer Of The Nutraceuticals Business Of The Company Please find enclosed announcement related to - Slump Sale and transfer of the Nutraceuticals business of the Company which is self explanatory for your records |
|
Tue, 27 Jul 2021
Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2021 We refer to our letter dated 12th July 2021 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 11.30 a.m. and concluded at 1.45 p.m. The Board approved unaudited financial results for the quarter and half year ended 30th June 2021. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose a copy of the unaudited financial results for the quarter and half year ended 30th June 2021 approved at this Meeting including the Statement of Assets and Liabilities as on that date and the Statement of Cash Flow for the half year ended 30th June 2021 along with a copy of the Limited Review Report duly signed by the Auditors of the Company. |
|
Thu, 15 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s) details of which are enclosed. |
| Mon, 02 Aug 2021 |
Close Crossing Last Week High
|
Close Crossing Last Month High
|
Close Crossing Last Month Close From Below
|
Opening at Low
|
Closing Above Previous High
|
Equities
M.F.
Sectors